Connolly Bove Lodge & Hutz LLP
Site-directed modification of FVIII
This invention relates to Factor VIII muteins that are covalently bound, at one or more predefined sites that are not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity, are capable of correcting human factor VIII deficiencies and have improved pharmacokinetic properties.
Bayer Healthcare LLC
A A A C A A C C A
A61P A61P A61K C07K A61K A61P C07K C07K A61K
inventional inventional inventional additional additional inventional inventional inventional inventional
Jonathan S. Thomas Baisong Hendri Deqian John E. Liang Jianmin Clark Q.
Strauss Barnett Mei Tjandra Wang Murphy Tang Chen Pan